AIG-Onco5

AIG-Onco5 is a small molecule drug candidate developed by Aigen Sciences in partnership with Incurix. It acts as a transcription factor inhibitor and is being investigated primarily for the treatment of lung cancer and other neoplasms. The drug targets transcription factors involved in cancer cell proliferation, aiming to disrupt oncogenic signaling pathways at the gene expression level. As of early 2024–2025, its development status was at the discovery or early research phase with no clinical trials reported or regulatory approvals granted. The therapeutic focus includes neoplasms and respiratory diseases such as lung cancer[1][2][9].